Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy
about
The potential impact of coinfection on antimicrobial chemotherapy and drug resistanceProportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patientsRisk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals.Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study.Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
P2860
Q28081282-CA40F6F9-12D7-46AF-9B91-8CBED2647E69Q35892317-0D559705-CEAD-4B64-A0AE-4F6A609B9994Q37409858-D15C9CDC-D0E5-403A-AB5F-35B89835A303Q38406226-020E430D-EF86-4738-9D4C-A8D97E6D463AQ40346742-FC4EB0D4-5F8A-45D5-A2FB-6F4FE563E487Q40627202-37440AA0-16CF-4C33-BBC8-196602449C97Q41931536-991E41FC-2693-4BDB-B13E-FA64F2E41CD2Q47556623-8F8ED138-FFAC-4BDD-A1AE-AE55BD6CA218
P2860
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence and risk factors for ...... iating tenofovir-based therapy
@en
Incidence and risk factors for ...... ating tenofovir-based therapy.
@nl
type
label
Incidence and risk factors for ...... iating tenofovir-based therapy
@en
Incidence and risk factors for ...... ating tenofovir-based therapy.
@nl
prefLabel
Incidence and risk factors for ...... iating tenofovir-based therapy
@en
Incidence and risk factors for ...... ating tenofovir-based therapy.
@nl
P2093
P2860
P356
P1476
Incidence and risk factors for ...... iating tenofovir-based therapy
@en
P2093
A R Localio
J R Kostman
J S Hafkin
M K Osborn
P De La Torre
V K Amorosa
P2860
P304
P356
10.1111/JVH.12142
P577
2013-07-30T00:00:00Z